
Harald Murck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9492345/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression. Journal of Clinical Psychopharmacology, 2003, 23, 155-168.	1.4	141
2	Magnesium-deficient diet alters depression- and anxiety-related behavior in mice—influence of desipramine and Hypericum perforatum extract. Neuropharmacology, 2004, 47, 1189-1197.	4.1	139
3	Magnesium and Affective Disorders. Nutritional Neuroscience, 2002, 5, 375-389.	3.1	130
4	Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. Journal of Psychiatric Research, 2004, 38, 129-136.	3.1	129
5	Elevated nocturnal profiles of serum leptin in patients with depression. Journal of Psychiatric Research, 1998, 32, 403-410.	3.1	125
6	Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology, 2000, 39, 1474-1481.	4.1	118
7	A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2005, 25, 441-447.	1.4	116
8	Growth Hormone-Releasing Peptide-6 Stimulates Sleep, Growth Hormone, ACTH and Cortisol Release in Normal Man. Neuroendocrinology, 1995, 61, 584-589.	2.5	115
9	Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?. Frontiers in Immunology, 2020, 11, 1239.	4.8	104
10	New paradigms for treatmentâ€resistant depression. Annals of the New York Academy of Sciences, 2013, 1292, 21-31.	3.8	89
11	The Renin-Angiotensin-Aldosterone system in patients with depression compared to controls – a sleep endocrine study. BMC Psychiatry, 2003, 3, 15.	2.6	88
12	St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology, 2002, 164, 294-300.	3.1	86
13	The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial. Schizophrenia Research, 2006, 84, 112-120.	2.0	83
14	Oral Mg2+ Supplementation Reverses Age-Related Neuroendocrine and Sleep EEG Changes in Humans. Pharmacopsychiatry, 2002, 35, 135-143.	3.3	72
15	Treatment of Somatoform Disorders With St. John's Wort: A Randomized, Double-Blind and Placebo-Controlled Trial. Psychosomatic Medicine, 2004, 66, 538-547.	2.0	71
16	Somatostatin Impairs Sleep in Elderly Human Subjects. Neuropsychopharmacology, 1997, 16, 339-345.	5.4	63
17	Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. International Journal of Neuropsychopharmacology, 2012, 15, 247-265.	2.1	62
18	On the Gender Differences in Sleep-Endocrine Regulation in Young Normal Humans. Neuroendocrinology, 1999, 70, 280-287.	2.5	61

#	Article	IF	CITATIONS
19	Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. Psychoneuroendocrinology, 2004, 29, 1205-1211.	2.7	61
20	Cortisol Enhances non-REM Sleep and Growth Hormone Secretion in Elderly Subjects. Neurobiology of Aging, 1997, 18, 423-429.	3.1	60
21	Renin-Angiotensin-Aldosterone System: The Forgotten Stress Hormone System: Relationship to Depression and Sleep. Pharmacopsychiatry, 2012, 45, 83-95.	3.3	60
22	Effects of Hormones on Sleep. Hormone Research in Paediatrics, 1998, 49, 125-130.	1.8	57
23	State Markers of Depression in Sleep EEG: Dependency on Drug and Gender in Patients Treated with Tianeptine or Paroxetine. Neuropsychopharmacology, 2003, 28, 348-358.	5.4	56
24	Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. Psychoneuroendocrinology, 2006, 31, 100-107.	2.7	56
25	Ketamine, magnesium and major depression – From pharmacology to pathophysiology and back. Journal of Psychiatric Research, 2013, 47, 955-965.	3.1	56
26	Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 57-61.	4.8	55
27	Enhanced Slow Wave Sleep in Patients with Prolactinoma. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2706-2710.	3.6	49
28	Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology, 1997, 132, 82-88.	3.1	48
29	Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression. International Journal of Neuropsychopharmacology, 2004, 7, 341-349.	2.1	47
30	Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacology, 2001, 155, 187-192.	3.1	45
31	Nocturnal Hormone Secretion and the Sleep EEG in Patients Several Months After Traumatic Brain Injury. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 354-360.	1.8	43
32	On the role of menopause for sleep-endocrine alterations associated with major depression. Psychoneuroendocrinology, 2003, 28, 401-418.	2.7	43
33	Target-based biomarker selection – Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression. Journal of Psychiatric Research, 2015, 66-67, 24-37.	3.1	42
34	The Somatostatin Analogue Octreotide Impairs Sleep and Decreases EEG Sigma Power in Young Male Subjects. Neuropsychopharmacology, 2004, 29, 146-151.	5.4	41
35	Galanin has REM-sleep deprivation-like effects on the sleep eeg in healthy young men. Journal of Psychiatric Research, 1999, 33, 225-232.	3.1	35
36	Atypical depression spectrum disorder – neurobiology and treatment. Acta Neuropsychiatrica, 2003, 15, 227-241.	2.1	34

#	Article	IF	CITATIONS
37	The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression – An MR spectroscopy study. Journal of Psychiatric Research, 2009, 43, 175-180.	3.1	34
38	Mg 2+ reduces ACTH secretion and enhances spindle power without changing delta power during sleep in men - possible therapeutic implications. Psychopharmacology, 1998, 137, 247-252.	3.1	33
39	Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology, 2004, 29, 851-860.	2.7	33
40	Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. Journal of Psychiatric Research, 2002, 36, 189-196.	3.1	31
41	St. John's wort extract LI160 for the treatment of depression with atypical features – A double-blind, randomized, and placebo-controlled trial. Journal of Psychiatric Research, 2010, 44, 760-767.	3.1	31
42	Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement. Psychoneuroendocrinology, 2005, 30, 29-37.	2.7	30
43	Ethyl-EPA in Huntington disease—Potentially relevant mechanism of action. Brain Research Bulletin, 2007, 72, 159-164.	3.0	30
44	Sub-chronic dietary tryptophan depletion – An animal model of depression with improved face and good construct validity. Journal of Psychiatric Research, 2012, 46, 239-247.	3.1	30
45	Renin-Angiotensin-Aldosterone System, HPA-Axis and Sleep-EEG Changes in Unmedicated Patients with Depression after Total Sleep Deprivation. Pharmacopsychiatry, 2006, 39, 23-29.	3.3	29
46	Genetic, Molecular and Clinical Determinants for the Involvement of Aldosterone and Its Receptors in Major Depression. Nephron Physiology, 2014, 128, 17-25.	1.2	27
47	Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 155-161.	1.4	26
48	Effects of Growth Hormoneâ€Releasing Peptideâ€6 on the Nocturnal Secretion of GH, ACTH and Cortisol and on the Sleep EEG in Man: Role of Routes of Administration. Journal of Neuroendocrinology, 1999, 11, 473-478.	2.6	24
49	Increase in Amino Acids in the Pons after Sleep Deprivation: A Pilot Study Using Proton Magnetic Resonance Spectroscopy. Neuropsychobiology, 2002, 45, 120-123.	1.9	24
50	Reboxetine Induces Similar Sleep-EEG Changes Like SSRI's in Patients with Depression. Pharmacopsychiatry, 2004, 37, 193-195.	3.3	24
51	Aging does not affect the sleep endocrine response to total sleep deprivation in humans. Neurobiology of Aging, 1999, 20, 665-668.	3.1	23
52	Hyporesponsiveness of the Pituitary to CRH during Slow Wave Sleep Is Not Mimicked by Systemic GHRH. Neuroendocrinology, 1999, 69, 88-96.	2.5	22
53	Early onset of depression and treatment outcome in patients with major depressive disorder. Journal of Psychiatric Research, 2021, 139, 150-158.	3.1	22
54	Changes in the sleep electroencephalogram (EEG) during male to female transgender therapy. Psychoneuroendocrinology, 2011, 36, 1005-1009.	2.7	20

#	Article	IF	CITATIONS
55	The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression – Lessons from primary aldosteronism. Journal of Psychiatric Research, 2020, 130, 82-88.	3.1	20
56	Pituitary adenylate cyclase-activating peptide affects homeostatic sleep regulation in healthy young men. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E853-E857.	3.5	18
57	Resting Membrane Properties of Locust Muscle and Their Modulation I. Actions of the Neuropeptides YGGFMRFamide and Proctolin. Journal of Neurophysiology, 1998, 80, 771-784.	1.8	17
58	Food Enrichment with Glycyrrhiza glabra Extract Suppresses ACE2 mRNA and Protein Expression in Rats—Possible Implications for COVID-19. Nutrients, 2021, 13, 2321.	4.1	16
59	Hypericum Extract Reverses S-Ketamine-Induced Changes in Auditory Evoked Potentials in Humans – Possible Implications for the Treatment of Schizophrenia. Biological Psychiatry, 2006, 59, 440-445.	1.3	15
60	Markers of mineralocorticoid receptor function. International Clinical Psychopharmacology, 2019, 34, 18-26.	1.7	15
61	Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. Innovations in Clinical Neuroscience, 2015, 12, 26S-40S.	0.1	15
62	Longtime Administration of Growth Hormone-Releasing Hormone (GHRH) does not Restore the Reduced Efficiency of GHRH on Sleep Endocrine Activity in 2 Old-Aged Subjects - a Preliminary Study. Pharmacopsychiatry, 1997, 30, 122-124.	3.3	14
63	Sub-chronic treatment with an extract of Hypericum perforatum (St John's wort) significantly reduces cortisol and corticosterone in the rat brain. European Neuropsychopharmacology, 2004, 14, 7-10.	0.7	14
64	Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. International Journal of Neuropsychopharmacology, 2005, 8, 215-221.	2.1	14
65	Effect of Sub-Chronic Treatment with Jarsin® (Extract of St John's Wort,Hypericum perforatum) at Two Dose Levels on Evening Salivary Melatonin and Cortisol Concentrations in Healthy Male Volunteers. Pharmacopsychiatry, 2006, 39, 13-15.	3.3	14
66	Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety. Journal of Psychiatric Research, 2021, 137, 376-382.	3.1	13
67	Temporal EEG dynamics of non-REM sleep episodes in humans. Brain Research, 2000, 861, 233-240.	2.2	12
68	Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls. Psychopharmacology, 1999, 141, 107-110.	3.1	10
69	Alpha-Helical CRH Exerts CRH Agonistic Effects on Sleep-Endocrine Activity in Humans. Neuropsychobiology, 2005, 52, 62-67.	1.9	9
70	Mineralocorticoid receptor-related markers and outcome of major depression. International Clinical Psychopharmacology, 2018, 33, 224-228.	1.7	9
71	Ventricular volume, white matter alterations and outcome of major depression and their relationship to endocrine parameters – A pilot study. World Journal of Biological Psychiatry, 2021, 22, 104-118.	2.6	9
72	Adjunct Therapy With Glycyrrhiza Glabra Rapidly Improves Outcome in Depression—A Pilot Study to Support 11-Beta-Hydroxysteroid Dehydrogenase Type 2 Inhibition as a New Target. Frontiers in Psychiatry, 2020, 11, 605949.	2.6	7

IF # ARTICLE CITATIONS Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers. Psychopharmacology, 2005, 180, 3.1 327-332. Magnesium and major depression., 0, , 313-332. 74 6 Effects of Hypericum Extract (LI160) on the Change of Auditory Evoked Potentials by Cortisol Administration. Neuropsychobiology, 2004, 50, 128-133. Aldosterone Action on Brain and Behavior., 2017, , 159-179. 76 4 The neurobiology of childhood traumaâ \in "aldosterone and blood pressure changes in a community sample. World Journal of Biological Psychiatry, 2021, , 1-9. 2.6 Sleep-endocrine effects of growth hormone-releasing hormone (GHRH) in patients with 78 3.1 3 schizophrenia. Journal of Psychiatric Research, 2018, 101, 1-4. Routinely accessible parameters of mineralocorticoid receptor function, depression subtypes and responsé prediction: a post-hoc analysis from the early medication change trial in major depressive disorder. World Journal of Biological Psychiatry, 2022, 23, 631-642. 79 2.6 Dr. David F. Horrobin. Prostaglandins Leukotrienes and Essential Fatty Acids, 2003, 69, 1-26. 80 2.2 1 REM sleep in patients with depression., 0, , 383-394. 1 Hypericum perforatum differentially affects corticosteroid receptor-mRNA expression in human 82 3.1 1 monocytic U-937 cells. Journal of Psychiatric Research, 2011, 45, 1170-1177. Society News: Eur. J. Lipid Sci. Technol. 7/2003. European Journal of Lipid Science and Technology, 2003, 1.5 105, 386-387. [P3–027]: RESULTS OF A PHASE 2 STUDY OF NELOTANSERIN, A NOVEL 5HT2A RECEPTOR INVERSE AGONIST, IN LEWY BODY DEMENTIA SUBJECTS EXPERIENCING VISUAL HALLUCINATIONS. Alzheimer's and Dementia, 2017, 84 0.8 0 13, P940. [P4â€"588]: EVALUATION OF THE NEUROPROTECTIVE EFFECT OF INTEPIRDINE IN AN IN VITRO OXYGEN/GLUCOSE DEPRIVATIONâ€INDUCED CYTOTOXICITY MODEL. Alzheimer's and Dementia, 2017, 13, P1579. F71. Neuroendocrine Determinants of Structural Brain Parameters and Treatment Outcome in Major 86 1.3 0 Depression. Biological Psychiatry, 2019, 85, S240. T81. Gait Disturbances in Major Depression: Is There a Relationship to Normal Pressure 1.3 Hydrocephalus?. Biological Psychiatry, 2019, 85, S160.